On November 13, 2026, B. Riley Securities reaffirmed its Buy rating on Journey Medical Corp (DERM).
Two of two firms active in the past 90 days rate the stock in the bullish tier. The consensus price targets from six analysts as of November 10, 2026, have a mean of $14.03, a median of $13.77 and a range of $13.13 to $15.75.
The Q4 FY2026 consensus calls for $0.00 in EPS on $23.18 million in revenue.
